The Top of the Tops of International Biotech and Pharma Pays a Visit to Berlin

BERLIN, Oct. 23, 2017 /CNW/ - From November 6 to 8, 2017, CityCube Berlin will host a virtual who's who on the international biotech scene. Investors, startups and leading decision makers from the biotech, pharmaceutical and finance sectors will gather for three days of intensive exchange at the international BIO-Europe. High-ranking guests will participate in workshops, panels and those popular pre-scheduled one-on-one meetings that make the conference so unique. The aim of the get-together is to foster innovative and value-generating ideas by uniting joint interests and expertise.

In 2017, Berlin will host the BIO-Europe with support from Berlin Partner and the regional Cluster for Healthcare Industry and Life Sciences HealthCapital which will showcase its activities to international guests and also work to bring regional actors together with decision makers from across Germany and abroad. The cluster's agenda will focus on support for internationalization, regional excellence and future-oriented innovation. Carolin Clement, head of Unit Biotech/Pharma at Berlin Partner for Business and Technology, which manages the HealthCapital cluster, noted: "Among our tasks are highlighting the life sciences region on an international level and facilitating the creation of new companies and cooperative activities. Tradeshows and congresses like BIO-Europe offer the ideal platform to do just that. We provide custom-made location tours and information to all guests, and our in-depth knowledge of the region's major business and science stakeholders, infrastructure and commercial sites makes it possible for us to generate the right contacts for each respective need."

The region's roughly 5,000 employees at over 230 companies make a significant contribution to the federal state's expanding expertise and economic strength. Roughly 80 % carry out R&D in the realm of biomedicine. Today, digitization is the theme driving many of these companies: "In the future, big data will be essential to the life sciences. The challenge will be to derive new knowledge from this multiplicity of complex data, for example in cancer research and in the field of personalized medicine," notes Dr. Kai Uwe Bindseil, manager of the HealthCapital cluster. Here, the emphasis is placed on first-class R&D facilities such the Berlin Institute of Health (BIH), which focuses on translational research and precision medicine.

BIO-Europe will no doubt generate considerable attention for Berlin among the global community of experts before, during and after the conference. International guests will be given a great opportunity to personally acquaint themselves with the capital as a leading location for the biotech and pharma industry. This is indeed the unique advantage of international meetings that take place at a different location each year. As cluster manager Dr. Bindseil argues, visitors to Berlin are consistently most fascinated by the impressive industry numbers, the verve of the city and its unique entrepreneurial spirit: "The large pool of international talent and the dynamic founders' scene continue to inspire companies from all over the world to come to Berlin and launch development centers here. Large pharmaceutical companies like Bayer and Pfizer seek out contact to startups and work with them on innovations and new business models in labs, incubators and special startup programs."

SOURCE Berlin Partner für Wirtschaft und Technologie GmbH

For further information: Lukas Breitenbach, Spokesman, Tel [phone], [email protected], Berlin Partner für Wirtschaft und Technologie GmbH, http://www.berlin-partner.de/en